NCIt definition : A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific
membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein
CD28, with potential immunostimulating and antineoplastic activities. Upon administration
of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes
(CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects
CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death
of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic
and hormone-refractory prostate cancer cells.;